#hiv vaccine

[fidicushiv]

Call : +917997101303 | Whatsapp : https://wa.me/917997101505 | Website : https://fidicus.com

HIV ఉన్నా వంద సంవత్సరాలు బతకాలంటే? | Advantages of Homeopathy In Treating HIV AIDS Treatment Cure

Discover how individuals living with HIV can lead a normal, healthy life using homeopathy medicines. In this video, we explore the natural and holistic approach of homeopathy to boost immunity, reduce viral load, and improve overall well-being. Learn how personalized homeopathic treatments can support your body's healing process, minimize symptoms, and enhance your quality of life without side effects. Stay informed and empowered with effective homeopathic care for HIV.

Dr. Bharadwaz | HIV AIDS | Health & Fitness | Homeopathy, Medicine & Surgery | Clinical Research

#HIVTreatment #HomeopathyForHIV #NaturalHealing #BoostImmunity #healthyliving

#DrBharadwaz #Helseform #Fidicus #Clingenious

#ClingeniousHealth #HelseformFitness #FidicusHomeopathy #ClingeniousResearch

#FidicusHIV #HIV #AIDS #HumanImmunodeficiencyViruses #AcquiredImmuneDeficiencySyndrome

#Treatment #Cure #Prevent #Relieve #Medicine #Vaccine

#AlternativeTherapy #AdjuvantTherapy #AlternativeMedicine #AlternativeSystem

Specialty Clinic Fidicus HIV highest success with homeopathy Improve Wellness | Increase Longevity | Addresses Questions

[chimericchaos]

Stg I am so happy the US media has not gotten a hold of STI treatment information

Like, I mean that while the results are promising, you just know that the US media is going to spin it into a horrible story like

'Anti-STI' miracle drug halted by lying women

When in reality, the drug focusing on preventing bacterial STI's by taking them the day after, Doxy-pep, has gotten great strides in clinical trials and is expected to be available to the US and worldwide soon. The problem being that within the trials, a number of women who were tested were found to have been lying about even taking the drug, for reasons still being looked into. This has given a statistical impact on the effectiveness of Doxy-pep based on gender, and currently it is recorded that Doxy-pep works best for "men who have sex with men or transgender women"

To reiterrate: The Drug Is Still Being Distributed. Everything is fine

This post is really just about how horrible the media is, and how much the average person *doesn't* look into things themselves for further information, blindly going by headlines and big bold text (if you are one of the few people who do look into things, thank you ever so much, I wish you all the sex you ever want in your lifetime)

Now, as one who personally loves rampant gay sex, I occasionally check up on the latest STI preventions, treatments and vaccinations. If you don't know what the STI scene currently looks like, the news is:

Syphalis - CURABLE

Gonorrhea - CURABLE

Chlamydia - CURABLE

Trichoniasis - CURABLE

Of course these are the four biggest bacterial STI's and can be treated with the right antibiotics. The real big scares are the viral STI's, like

Hepatitis B - NO CURE

HSV - NO CURE

HPV - NO CURE

HIV - NO CURE

These four are the big ones, the reasons why I can't get too drunk at my local bar. The biggest of those is obviously HIV, the others likely to get a boost in research once a HIV vaccine materializes

There is no HIV vaccine *yet* however there are over 20 ongoing trials, with a few seeing successful results. While things are currently in Phase 1 for the most part, it's possiple for Phase 2 to start soon, moving on through more rigourous testing and eventually making a HIV vaccine possible. Results will unfortunately take some time

[drpedi07]

AIDS and HIV

AIDS vaccine is possible. The neutralizing HIV antibodies have been identified thus vaccines that can lead to the formation of these neutralizing antibodies can lead to protection. 

[reasonsforhope]

"Since it was first identified in 1983, HIV has infected more than 85 million people and caused some 40 million deaths worldwide.

While medication known as pre-exposure prophylaxis, or PrEP, can significantly reduce the risk of getting HIV, it has to be taken every day to be effective. A vaccine to provide lasting protection has eluded researchers for decades. Now, there may finally be a viable strategy for making one.

An experimental vaccine developed at Duke University triggered an elusive type of broadly neutralizing antibody in a small group of people enrolled in a 2019 clinical trial. The findings were published today [May 17, 2024] in the scientific journal Cell.

“This is one of the most pivotal studies in the HIV vaccine field to date,” says Glenda Gray, an HIV expert and the president and CEO of the South African Medical Research Council, who was not involved in the study.

A few years ago, a team from Scripps Research and the International AIDS Vaccine Initiative (IAVI) showed that it was possible to stimulate the precursor cells needed to make these rare antibodies in people. The Duke study goes a step further to generate these antibodies, albeit at low levels.

“This is a scientific feat and gives the field great hope that one can construct an HIV vaccine regimen that directs the immune response along a path that is required for protection,” Gray says.

-via WIRED, May 17, 2024. Article continues below.

Vaccines work by training the immune system to recognize a virus or other pathogen. They introduce something that looks like the virus—a piece of it, for example, or a weakened version of it—and by doing so, spur the body’s B cells into producing protective antibodies against it. Those antibodies stick around so that when a person later encounters the real virus, the immune system remembers and is poised to attack.

While researchers were able to produce Covid-19 vaccines in a matter of months, creating a vaccine against HIV has proven much more challenging. The problem is the unique nature of the virus. HIV mutates rapidly, meaning it can quickly outmaneuver immune defenses. It also integrates into the human genome within a few days of exposure, hiding out from the immune system.

“Parts of the virus look like our own cells, and we don’t like to make antibodies against our own selves,” says Barton Haynes, director of the Duke Human Vaccine Institute and one of the authors on the paper.

The particular antibodies that researchers are interested in are known as broadly neutralizing antibodies, which can recognize and block different versions of the virus. Because of HIV’s shape-shifting nature, there are two main types of HIV and each has several strains. An effective vaccine will need to target many of them.

Some HIV-infected individuals generate broadly neutralizing antibodies, although it often takes years of living with HIV to do so, Haynes says. Even then, people don’t make enough of them to fight off the virus. These special antibodies are made by unusual B cells that are loaded with mutations they’ve acquired over time in reaction to the virus changing inside the body. “These are weird antibodies,” Haynes says. “The body doesn’t make them easily.”

Haynes and his colleagues aimed to speed up that process in healthy, HIV-negative people. Their vaccine uses synthetic molecules that mimic a part of HIV’s outer coat, or envelope, called the membrane proximal external region. This area remains stable even as the virus mutates. Antibodies against this region can block many circulating strains of HIV.

The trial enrolled 20 healthy participants who were HIV-negative. Of those, 15 people received two of four planned doses of the investigational vaccine, and five received three doses. The trial was halted when one participant experienced an allergic reaction that was not life-threatening. The team found that the reaction was likely due to an additive in the vaccine, which they plan to remove in future testing.

Still, they found that two doses of the vaccine were enough to induce low levels of broadly neutralizing antibodies within a few weeks. Notably, B cells seemed to remain in a state of development to allow them to continue acquiring mutations, so they could evolve along with the virus. Researchers tested the antibodies on HIV samples in the lab and found that they were able to neutralize between 15 and 35 percent of them.

Jeffrey Laurence, a scientific consultant at the Foundation for AIDS Research (amfAR) and a professor of medicine at Weill Cornell Medical College, says the findings represent a step forward, but that challenges remain. “It outlines a path for vaccine development, but there’s a lot of work that needs to be done,” he says.

For one, he says, a vaccine would need to generate antibody levels that are significantly higher and able to neutralize with greater efficacy. He also says a one-dose vaccine would be ideal. “If you’re ever going to have a vaccine that’s helpful to the world, you’re going to need one dose,” he says.

Targeting more regions of the virus envelope could produce a more robust response. Haynes says the next step is designing a vaccine with at least three components, all aimed at distinct regions of the virus. The goal is to guide the B cells to become much stronger neutralizers, Haynes says. “We’re going to move forward and build on what we have learned.”

-via WIRED, May 17, 2024

[covid-safer-hotties]

Also preserved in our archive

HIV/AIDS & COVID-19, particularly long COVID, share several significant similarities, especially in terms of viral persistence, T cell damage, immune system dysfunction, & activation of other pathogens. These parallels are important for understanding the long-term effects of both infections and their impact on the immune system.

1. Viral Persistence

Both HIV & SARS-CoV-2 can persist in the body, leading to chronic symptoms & immune system complications. In HIV, the virus establishes reservoirs in various tissues, allowing it to evade immune detection and antiretroviral therapy (ART), leading to lifelong infection. Similarly, recent studies at Brigham and Women’s Hospital suggest that a subset of people with long COVID may harbor persistent SARS-CoV-2 proteins in their blood, potentially explaining ongoing symptoms months after the acute infection has resolved[4][10]. This viral persistence is thought to drive chronic inflammation and immune dysfunction in both.

In long COVID, viral reservoirs have been identified in multiple organs, including the gut, blood, & nervous system[12]. This mirrors HIV's ability to persist in tissue reservoirs such as lymphoid tissues. For both viruses, this persistence can lead to prolonged immune activation & may contribute to ongoing symptoms like fatigue, cognitive issues, & cardiovascular problems.

2. T Cell Damage & Exhaustion

Both HIV and SARS-CoV-2 cause significant damage to T cells, particularly CD4+ T cells. In HIV infection, CD4+ T cells are directly targeted by the virus, leading to their depletion over time and resulting in severe immunodeficiency if untreated. Similarly, severe COVID-19 has been associated with a reduction in CD4+ T cells due to excessive immune activation and exhaustion[1][2]. In both, CD8+ T cells also become dysfunctional due to chronic exposure to viral antigens.

T cell exhaustion is a common feature in both infections. In HIV, chronic infection leads to high levels of inhibitory receptors like PD-1 on T cells, contributing to their reduced functionality[2]. In severe COVID-19 cases, similar markers of T cell exhaustion (e.g., PD-1 and TIM-3) are observed[1]. This exhaustion impairs the body's ability to clear the virus effectively and contributes to prolonged illness.

3. Immune System Dysfunction

Both HIV/AIDS & long COVID can lead to profound immune system dysfunction. In HIV infection, even with effective ART, individuals often experience chronic immune activation and systemic inflammation due to incomplete immune recovery[6][9]. This persistent immune activation is linked to increased susceptibility to other infections and long-term health complications.

Similarly, long COVID is believed to involve ongoing immune dysregulation even after the acute phase of SARS-CoV-2 infection has passed. Some studies suggest that persistent viral proteins may continue stimulating the immune system, leading to chronic inflammation[4][12]. This ongoing immune activation may explain why some individuals experience prolonged symptoms such as fatigue, brain fog, or cardiovascular issues even after clearing the virus from most tissues.

4. Activation of Other Pathogens

Both HIV/AIDS and long COVID are associated with the reactivation of latent pathogens due to weakened immune surveillance. In people living with HIV (PLWH), co-infections with viruses like Epstein-Barr virus (EBV) or cytomegalovirus (CMV) are common due to compromised immunity[7]. Similarly, studies have shown that reactivation of latent viruses such as EBV may contribute to long COVID symptoms[7]

In both conditions, the weakened immune system's inability to control these latent infections can exacerbate symptoms and complicate recovery. For example, EBV reactivation has been linked with neurocognitive symptoms in long COVID patients[7], while opportunistic infections such as Pneumocystis jirovecii pneumonia are common in advanced HIV/AIDS patients[3]

So, HIV/AIDS and long COVID share several key similarities regarding viral persistence, T cell damage, immune system dysfunction, and the reactivation of other pathogens. These shared features highlight the importance of understanding how chronic viral infections can lead to long-term health consequences through mechanisms like persistent viral reservoirs and ongoing immune activation. Insights from HIV research may help inform treatment strategies for long COVID, especially in targeting viral persistence with antiviral therapies or addressing chronic immune dysfunction.

Sources

[1] SARS-CoV-2 and HIV-1: So Different yet so Alike. Immune ... pmc.ncbi.nlm.nih.gov/articles/PMC9608044/

[2] Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on ... www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.596631/full

[3] Overview of SARS-CoV-2 infection in adults living with HIV www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00070-9/fulltext

[4] Study Finds Persistent Infection Could Explain Long COVID in Some ... www.massgeneralbrigham.org/en/about/newsroom/press-releases/study-finds-persistent-infection-could-explain-long-covid-in-some-people

[5] New COVID studies show varied viral clearance time in patients with ... www.cidrap.umn.edu/covid-19/new-covid-studies-show-varied-viral-clearance-time-patients-lower-immunity

[6] Immunologic Interplay Between HIV/AIDS and COVID-19 link.springer.com/article/10.1007/s11904-023-00647-z

[7] Long COVID in people living with HIV - PMC - PubMed Central pmc.ncbi.nlm.nih.gov/articles/PMC10167544/

[8] Persistence and Evolution of SARS-CoV-2 in an ... - NCBI www.ncbi.nlm.nih.gov/pmc/articles/PMC7673303/

[9] The immune response to SARS-CoV-2 in people with HIV - Nature www.nature.com/articles/s41423-023-01087-w

[10] Persistent infection could explain long COVID in some people, study ... www.sciencedaily.com/releases/2024/10/241009122346.htm

[11] Plasma-based antigen persistence in the post-acute phase of ... www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00211-1/fulltext

[12] Long Covid trials aim to clear lingering virus—and help patients in ... www.science.org/content/article/long-covid-trials-aim-clear-lingering-virus-help-patients-need

[mindblowingscience]

For a vaccine to work, it has to raise antibodies in the immunized – antibodies that are primed to neutralize subsequent intruders. For a vaccine to be safe, it has to do so for the vast majority without major side effects or reactions. A new vaccine candidate for HIV is facing those familiar challenges in early-stage clinical trials, succeeding in one aspect but encountering some hurdles in the other. It's still progress though, as its developers have reformulated the vaccine to improve its safety in future studies – while their latest results show how the vaccine successfully generates broadly neutralizing antibodies in a small number of people.

Continue Reading.

[neallo]

hi holy fucking shit?

[allthegeopolitics]

NFL star Aaron Rodgers has shocked fans by claiming that Aids was manufactured by the US government. Aaron Rodgers said the HIV/Aids pandemic of the 1980s was engineered to said drive sales of vaccinations. The New York Jets quarterback further claimed that the crisis was a “blueprint” for the COVID-19 pandemic and specifically blamed former chief medical advisor Dr Anthony Fauci for the conspiracy.

Continue Reading

[onetwistedmiracle]

Twice-a-year shot provides 100 percent HIV protection, study finds

None of the 5,000 women and girls in South Africa and Uganda who received the shots contracted the virus that causes AIDS, a study shows. A trial for men is underway.

By Rachel Pannett for The Washington Post

July 25, 2024 at 1:05 a.m. EDT

A twice-yearly injection could help prevent HIV infections, according to the results of a new study described by medical experts as a breakthrough.

In a randomized trial involving more than 5,000 young women and girls in South Africa and Uganda, none of those who received the prevention shots contracted HIV. The results were published in the New England Journal of Medicine on Wednesday.

“This appears to be a new breakthrough for HIV prevention. If these injections can be widely distributed at low cost, it would dramatically reduce the risk of new HIV infections worldwide,” said Sarah Palmer, co-director of the Center for Virus Research at the Westmead Institute for Medical Research in Sydney, who was not involved in the peer-reviewed study. “It is especially encouraging this research focused on young women in Africa who are so highly at-risk for HIV infection.”

Worldwide there are about 1.3 million new HIV infections every year, with women and girls accounting for 44 percent of them. In sub-Saharan Africa, that proportion is 62 percent.

The shots were produced by drugmaker Gilead Sciences, which funded the trial, and some of the researchers were Gilead employees. Lenacapavir, sold under the brand name Sunlenca, is approved as a treatment for HIV infections in the United States. The goal of the trial was to prove its safety and efficacy for the prevention of infection in adolescent girls and young women. A separate trial for men is underway.

When it became clear that the shots were more effective than daily pills — 1.5 percent to 1.8 percent of participants who received one of two daily pills as part of the trial contracted HIV from their partners — the trial was halted and all participants were offered the option of receiving the injections, the researchers said. The researchers also found the incidence of HIV was lower with the use of the shots than the usual rate of HIV in the community.

HIV can be prevented through the use of protective measures such as condoms and daily pills that are in wide use in high-income countries around the world. But health experts say it can be difficult to maintain a daily pill routine in places like Africa, where limited access to health care and a dearth of educational programs put girls at particular risk for HIV.

Doctors Without Borders and other groups are calling for global action to break Gilead’s monopoly on lenacapavir to allow mass production of the drug and reduce its cost. Gilead charges $42,250 per patient per year for lenacapavir in the United States.

“Lenacapavir could be life-changing for people at risk of getting HIV and could reverse the epidemic if it is made affordable in the countries with the highest rate of new infections,” said Helen Bygrave, a chronic disease adviser at Doctors Without Borders.

Gilead previously said it was committed to lowering the cost of its drugs in low-income countries.

By Rachel Pannett

Rachel Pannett joined the Post's foreign desk in 2021 after more than a decade with The Wall Street Journal, where she was deputy bureau chief for Australia and New Zealand. Twitter

[specters]

i like going to pride not just to see other lgbt people but also because i love free shit 👍

[kramlabs]

https://jimhaslam.substack.com/p/timeline-for-the-creation-and-cover

[drpedi07]

AIDS and HIV

AIDS vaccine is possible. The neutralizing HIV antibodies have been identified thus vaccines that can lead to the formation of these neutralizing antibodies can lead to protection. 

[reasonsforhope]

"Five people have gone into remission thanks to advancements in medicine — and a sixth patient may also now be free of HIV.

One of the biggest breakthroughs in HIV/AIDS prevention in recent years is the widespread use of PrEP (pre-exposure prophylaxis). 

This drug therapy, approved by the Federal Drug Administration in 2012, has been a key player in preventing HIV transmission through sex or injection drug use. Antiretroviral drugs, such as PrEP, also slow the replication of the virus and prevent it from progressing to AIDS.

Although PrEP has become a more accessible treatment for the virus, scientists have been hurriedly working towards cures for HIV for decades — and we’re finally seeing some results.

In February of this year, scientists in Germany confirmed a fifth-ever patient had been cured of HIV after receiving stem cell transplants that include genetic mutations that carry a resistance to HIV. 

But it looks like a sixth patient may soon be able to join this very exclusive club. 

The man, referred to as the ��Geneva patient,” underwent a stem cell transplant after cancer treatment, though these cells did not include the HIV-resistant genetic mutation. 

Still, he went off antiretroviral therapy for HIV in November 2021, and his viral load remains undetectable. 

Instead, doctors are researching whether a drug called ruxolitinib may be partially responsible for his recovery. 

Ruxolitinib decreases inflammation associated with HIV by blocking two proteins, JAK1 and JAK2. This helps kill off “reservoir cells” that lay dormant in the body and have a potential to cause rebounds in patients with HIV.

Experts say the AIDS crisis can end by 2030 across the globe — as long as leaders prioritize this goal. 

A new report from UNAIDS shows a clear, optimistic path to ending the AIDS crisis. (This looks like a 90% reduction in cases by 2030.)

The organization’s report includes data and case studies that show that ending AIDS is a political and financial choice — and that governments that have prioritized a path towards progress are seeing extraordinary results.

By following the data, science, and evidence; tackling inequality; and ensuring sufficient and sustainable funding across communities, the global community could wipe out the AIDS pandemic by the end of the decade.

The report demonstrates that progress has been strongest in the countries and regions that have the most financial investments, like eastern and southern Africa, where new HIV infections have been reduced by 57% since 2010. 

Investments in treatments, education, and access to care have also led to a 58% reduction in new HIV infections among children from 2010 to 2022 — the lowest number since the 1980’s.

Plus, the number of people on antiretroviral treatment around the globe has risen from 7.7 million in 2010 to 29.8 million in 2022.

The moral of the story? This goal can be achieved, if world leaders put their minds — and wallets — to it. 

A region in Australia might be the first place in the world to reach the United Nations targets for ending HIV transmission. 

Researchers believe that the central district of Sydney, Australia is close to becoming the first locality in the world to reach the UN’s target for ending transmission of HIV. 

Specifically, new infections among gay men have fallen by 88% between 2010 and 2022. In fact, there were only 11 new HIV cases recorded in central Sydney last year, and almost all HIV-positive Australians are on antiretroviral drugs. 

... "These numbers show us that virtual elimination of HIV transmissions is possible. Now, we need to look closely at what has worked in Sydney, and adapt it for other cities and regions across Australia.”

Namibia is ahead of schedule in UN targets to end HIV/AIDS. 

Although the virus is still the leading cause of death in Namibia, the country is well on track to hit 95-95-95 UNAIDS targets before its 2030 deadline. 

In Namibia, 92% of people know their HIV status, 99% of people living with HIV are on treatment, and 94% of people living with HIV who are on treatment are virally suppressed.

In addition to these exciting statistics, new infections have plummeted. The estimated rate of new HIV infections in Namibia is five times lower than it was in 2002, according to the Centers for Disease Control & Prevention.

These encouraging numbers are thanks to the investment and strategic response of PEPFAR, but also to the willingness of local governmental agencies and organizations to adhere to the UN’s Fast-Track approach.

Breakthroughs are being made in HIV vaccine therapies.

Long before we were all asking each other “Pfizer or Moderna?” about our COVID-19 vaccines, scientists have been researching the potential of mRNA vaccines in treating some of the world’s deadliest diseases — like HIV.

And with the success of our mainstream mRNA vaccines, an HIV inoculation remains a goal for researchers across the globe.

Last year, the National Institutes of Health launched a clinical trial of three mRNA vaccines for HIV, and similar studies are being conducted in Rwanda and South Africa, as well. 

CAR T-cell clinical trials are underway to potentially cure HIV.

This spring, UC Davis Health researchers have dosed the second participant in their clinical trial, which poses the use of CAR T-cell therapy as a potential cure for HIV.

The study involves taking a participant’s own white blood cells (called T-cells), and modifying them so they can identify and target HIV cells, ultimately controlling the virus without medication. 

The first participant in the study was dosed with anti-HIV T-cells last August, and the trial is the first of its kind to utilize this technology to potentially treat HIV. 

Of course, the trials have a long way to go, and the lab is still preparing to dose a third participant for the study, but CAR T-cell treatments have been successful for lupus and forms of cancer in the past...

“So far, there have been no adverse events observed that were related to the treatment, and the two participants are doing fine.”

Guidance on how to reduce stigma and discrimination due to HIV/AIDS is reaching people around the globe.

While the stigma surrounding HIV and AIDS has significantly decreased — especially towards the LGBTQ+ community — with advancements in treatment and prevention, discrimination is certainly not gone. 

While most people now understand HIV/AIDS better than they did decades ago, those most impacted by the virus (like gay men and low-income women and children) still face ongoing barriers to care and economic security. 

It is vital to maintain awareness and education interventions. 

After all, experts suggest that eliminating discrimination and stigma are key factors in reducing disease.  And not eliminating stigma impedes HIV services, argues UNAIDS, “limiting access to and acceptance of prevention services, engagement in care, and adherence to antiretroviral therapy.” 

Luckily, UNAIDS provides guidance on how to reduce stigma and discrimination in the community, workplace, education, health care, justice, and emergency settings. 

The goal is to, of course, decrease stigma in order to decrease disease, but also to provide folks with the culturally significant support they need to live safe, integrated lives — with or without disease. 

For instance, a 2022 study conducted in Northern Uganda showed that local cultural knowledge passed through Elders was a successful intervention in reducing HIV-related stigma among young people.

“Research in school settings has shown that the use of local cultural stories, songs, myths, riddles, and proverbs increases resilient coping responses among students and strengthens positive and socially accepted morals and values,” the study’s discussion reads. 

So, while an uptick in acceptance gives us hope, it also gives us a directive: Keep telling the accurate, full, and human stories behind HIV/AIDS, and we’ll all be better for it. "

-via GoodGoodGood, August 3, 2023